Skip to main content
Premium Trial:

Request an Annual Quote

Case Medical Center to Offer Exact's DNA Screening Test for Colon Cancer

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Exact Sciences said Monday that University Hospitals Case Medical Center of Cleveland has launched a program for stool-based DNA screening at two sites within its system.
Marlborough, Mass.-based Exact Sciences makes a stool-based DNA test for colorectal cancer screening, which is offered by licensing partner Laboratory Corporation of America. Earlier this year, its screening technology was included in the American Cancer Society’s updated guidelines for colorectal cancer screening.
According to the firm, its stool-based DNA test will be the preferred method for screening patients who are unwilling or unable to obtain a colonoscopy. Exact’s test screens for the Vimentin gene, which was discovered by a researcher at Case Western Reserve University.
The center intends to evaluate the program's performance to determine whether it will roll out the DNA screening program system-wide.
Case Medical Center’s decision to offer the stool-based DNA screening test follows an announcement last week by the Massachusetts Department of Public Health that it had added the test as an option for its Massachusetts Care Coordination Program for low-income men and women over age 40.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.